Cold virus turned cancer killer enters human trials
NCT ID NCT06977737
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests ATTR-01, a modified cold virus designed to infect and multiply only in cancer cells, delivering an immune-boosting drug directly into the tumor. The study involves 72 adults with solid tumors who have not responded to standard treatments. The goal is to see if the virus is safe and can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ATTR-01 (a modified common cold virus that infects and kills cancer cells while delivering immune therapy)
What this could lead to
If successful, this could point toward a new treatment option for certain solid tumors that have not responded to standard therapies.
What could go wrong
This is the first human study, so safety and effectiveness are unknown. The trial is small (72 people) and early-stage, so results may not lead to a widely available treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
, St James' University Hospital
RECRUITINGLeeds, United Kingdom
-
Beatson West of Scotland Cancer Centre
RECRUITINGGlasgow, Scotland, United Kingdom
-
Churchill Hospital
RECRUITINGOxford, United Kingdom
-
General Hospital San Pedro - START
NOT_YET_RECRUITINGRioja, Spain
-
START Barcelona
RECRUITINGBarcelona, Spain
-
Start Fjd
RECRUITINGMadrid, Spain
-
Start Hm Ciocc
RECRUITINGMadrid, Spain
-
Velindre Cancer Centre
RECRUITINGCardiff, Wales, United Kingdom